3-Year FIREFLY-1 Findings in pLGG: A Look at Long-Term Outcomes
Alexandria May, PharmD, BCPS
Daniel Landi, MD
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
Saad Z. Usmani, MD, MBA
Natalie S. Callander, MD
The Frontline Imperative: Integrating Anti-CD38–Based Regimens Into Multiple Myeloma Care in Community Practice
Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
Sagar Lonial, MD, FACP
Counseling Patients on Myelofibrosis Treatment Goals and Expectations
Shelina Ramnarine, PhD
John Mascarenhas, MD
Marina Kremyanskaya, MD
Gastric Cancer Prevention: A Risk-Based Approach
Peter Buch, MD, FACG, AGAF, FACP
Chul Hyun, MD, PhD, MPH
Improving Long-Term Adherence to CRC Screening Recommendations
Brian P. McDonough, MD, FAAFP
David A. Lieberman, MD
Factors Guiding First-Line Treatment Decisions for Myelofibrosis and Anemia
Charles Turck, PharmD, BCPS, BCCCP
Douglas A. Tremblay, MD
Evidence-Based Care for PD-L1-Negative Non-Small Cell Lung Cancer
Steve Jackson, PharmD
Apar Kishor Ganti, MD
Thomas Marron, MD, PhD
Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
Amer Zeidan, MBBS
Ghayas Issa, MD
Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Targeting TROP2 in EGFR-Mutated Advanced NSCLC: Navigating the ADC Revolution After TKI Failure
Multiple dates available
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
Axatilimab’s Impact on cGVHD and Associated BOS
Amandeep Salhotra, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.